The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: 10% holder buying, Insider buying cluster — insiders or holders bought while this setup is live; see the timeline.
Radar 93 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 2.0 mo · strongest signal: Insider buying cluster (Aug 14, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going concern in 8-k) coexists with live selling machinery (atm program, registered direct, shelf effective, shelf filed, offering (424b), warrant inducement). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
A fresh shelf is on file with under a year of cash — the ingredients of an offering before the next 10-K. First shelf registration in 12 months filed with ~2.0 months of runway. Companies rarely file a shelf they do not intend to use.
On August 12–14, 2026, Outlook Therapeutics (OTLK) completed a $55.0 million public offering at $0.99 per share-plus-warrant unit (55,555,556 shares) for net proceeds of ~$51.1 million. The offering closed shortly after the July 24, 2026 FDA approval of LYTENAVA for wet AMD. As of June 30, 2026, the company had $11.2 million cash (unaudited), implying roughly 2 months of runway on annualized Q2 burn of ~$45.9 million per year. In connection with the offering, the company terminated its ATM facility (effective August 10, 2026), issued warrants to purchase 55,555,556 shares at $1.10 (5-year expiry), and saw a 46% share count jump from 83.1 million (February 13, 2026) to 120.9 million (May 12, 2026). Major shareholder GMS Ventures and insider Ghiath Sukhtian bought $2.6 million of stock in open-market purchases between July 29 and August 14, 2026.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 138 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▲ Insider buying cluster | 4 open-market buys by 4 insider(s) (~$2,599,996) in 30d: KENYON LAWRENCE A 101,[email protected] 2026-08-14; Sukhtian Faisal Ghiath 95,[email protected] 2026-07-29; Jahr Robert Charles 151,[email protected] 2026-08-14; Sukhtian Ghiath M. 2,525,[email protected] 2026-08-12 filing | 59 |
| Aug 14, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-08-14; 7 prior 424B filings in 12m filing | 48 |
| Aug 14, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (EX-99.1) filed 2026-08-14 filing | 43 |
| Aug 14, 2026 | ▲ 10% holder buying | 10% holder open-market purchases: Sukhtian Ghiath M. 2,525,[email protected] filing | 42 |
| Aug 14, 2026 | ▼ ATM program | “atm” language in 424B5 (424B5) filed 2026-08-14 filing | 38 |
| Aug 14, 2026 | ▼ Registered direct | “rdo” language in 424B5 (424B5) filed 2026-08-14 filing | 34 |
| Aug 14, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-08-14 filing | 32 |
| Aug 14, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-1.1) filed 2026-08-14 filing | 32 |
| Aug 14, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-14 filing | 24 |
| Aug 14, 2026 | · Form 4 burst | 6 Form 4 filings in 30 days filing | 15 |
| Aug 12, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-08-12; 6 prior 424B filings in 12m filing | 48 |
| Aug 12, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-08-12 filing | 42 |
| Aug 12, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-08-12 filing | 38 |
| Aug 12, 2026 | ▼ ATM program | “atm” language in 424B5 (424B5) filed 2026-08-12 filing | 38 |
| Aug 12, 2026 | ▼ Registered direct | “rdo” language in 8-K (EX-99.1) filed 2026-08-12 filing | 36 |
| Aug 12, 2026 | ▼ Registered direct | “rdo” language in 424B5 (424B5) filed 2026-08-12 filing | 34 |
| Aug 12, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-08-12 filing | 32 |
| Aug 12, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-08-12 filing | 32 |
| Aug 12, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K (EX-99.1) filed 2026-08-12 filing | 31 |
| Jul 24, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-24 (accepted 19:54 ET) filing | 25 |
| Jul 21, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-07-21; 5 prior 424B filings in 12m filing | 28 |
| Jul 21, 2026 | ▼ Shelf effective | EFFECT notice 2026-07-21 filing | 21 |
| Jul 17, 2026 | ▼ Shelf filed | S-3 filed 2026-07-17 filing | 39 |
| Jul 17, 2026 | ▼ ATM program | “atm” language in S-3 (S-3) filed 2026-07-17 filing | 34 |
| Mar 31, 2026 | ▼ Runway < 6 months | ~2.0 months runway: liquidity $7,748,226 as of 2026-03-31, burn $45,911,688/yr (annualized 181-day YTD operating cash flow [companyfacts]) filing | 41 |
| Mar 31, 2026 | ▼ Share count +25% | Shares outstanding 83,067,190 (2026-02-13) -> 120,863,252 (2026-05-12), +46% filing | 35 |
| Mar 31, 2026 | ▼ Negative equity | Stockholders' equity $-28,994,771 as of 2026-03-31 filing | 31 |
| Mar 31, 2026 | ▼ Cash < current liabilities | Liquidity $7,748,226 vs current liabilities $38,883,990 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →